Tag: DESTINY-Breast04

Home / DESTINY-Breast04

Categories

Fam-trastuzumab deruxtecan-nxki is approved by FDA for HER2-low breast cancer

August 2022: For adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH) breast cancer who have received prior chemotherapy in the metastatic setting or experienced a disease r...
destiny-breast04

We Are Online! Chat With Us!
Scan the code